Therapeutic strategies for COVID-19: progress and lessons learned

G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Therapeutic advances in COVID-19

N Murakami, R Hayden, T Hills, H Al-Samkari… - Nature Reviews …, 2023 - nature.com
Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …

[HTML][HTML] Features, evaluation, and treatment of coronavirus (COVID-19)

M Cascella - 2020 - ncbi.nlm.nih.gov
Objectives: Screen individuals based on exposure and symptom criteria to identify potential
COVID-19 cases. Identify the clinical features and radiological findings expected in patients …

Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials

A Amstutz, B Speich, F Mentré, CS Rueegg… - The Lancet …, 2023 - thelancet.com
Background Interpretation of the evidence from randomised controlled trials (RCTs) of
remdesivir in patients treated in hospital for COVID-19 is conflicting. We aimed to assess the …

Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China

L Yang, Z Wang - European journal of medicinal chemistry, 2023 - Elsevier
The ongoing COVID-19 pandemic has resulted in millions of deaths globally, highlighting
the need to develop potent prophylactic and therapeutic strategies against SARS-CoV-2 …

Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants

C Sun, C Xie, GL Bu, LY Zhong, MS Zeng - Signal Transduction and …, 2022 - nature.com
The persistent COVID-19 pandemic since 2020 has brought an enormous public health
burden to the global society and is accompanied by various evolution of the virus genome …

Association of remdesivir treatment with mortality among hospitalized adults with COVID-19 in the United States

AP Chokkalingam, J Hayden, JD Goldman… - JAMA Network …, 2022 - jamanetwork.com
Importance SARS-CoV-2, which causes COVID-19, poses considerable morbidity and
mortality risks. Studies using data collected during routine clinical practice can supplement …

Innate immune inflammatory cell death: PANoptosis and PANoptosomes in host defense and disease

W Chen, JM Gullett, RE Tweedell… - European Journal of …, 2023 - Wiley Online Library
Regulated cell death (RCD) triggered by innate immune activation is an important strategy
for host survival during pathogen invasion and perturbations of cellular homeostasis. There …

Oral GS-441524 derivatives: Next-generation inhibitors of SARS‐CoV‐2 RNA‐dependent RNA polymerase

Z Wang, L Yang, X Song - Frontiers in immunology, 2022 - frontiersin.org
GS-441524, an RNA‐dependent RNA polymerase (RdRp) inhibitor, is a 1′-CN-substituted
adenine C-nucleoside analog with broad-spectrum antiviral activity. However, the low oral …

Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance

JD Ip, AWH Chu, WM Chan, RCY Leung… - …, 2023 - thelancet.com
Summary Background Nirmatrelvir-ritonavir (Paxlovid) and ensitrelvir are 3-chymotrypsin-
like cysteine protease (3CL pro) inhibitors which have been approved for the treatment of …